Citigroup Maintains Buy on Pear Therapeutics, Lowers Price Target to $12
Citigroup analyst Neena Bitritto-Garg maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $13 to $12.
Earnings Scheduled For March 28, 2022
Companies Reporting Before The Bell
• LGL Group (AMEX:LGL) is likely to report quarterly earnings at $0.10 per share on revenue of $7.20 million.
Pear Therapeutics, SoftBank Team On Sleep/Wake Disorder Therapeutic For Japanese Market
Pear Therapeutics Inc (NASDAQ: PEAR) has agreed with SoftBank Group Corp (OTC: SFTBY) to develop a Japanese-language digital therapeutic for sleep/wake disorders for the Japanese market.
46 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Indonesia Energy Corporation Limited (NASDAQ: INDO) shares jumped 158.2% to $7.23 after tumbling 18% on Wednesday. Indonesia Energy said it projects to commence drilling of 2 back-to-back new wells within 30 days and a third by mid-year.
Credit Suisse Initiates Coverage On Pear Therapeutics with Outperform Rating, Announces Price Target of $11
Credit Suisse analyst Judah Frommer initiates coverage on Pear Therapeutics (NASDAQ:PEAR) with a Outperform rating and announces Price Target of $11.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
45 Biggest Movers From Yesterday
Gainers
ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55.
61 Biggest Movers From Yesterday
Gainers
Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.